Cell-Specific Targets and Functions of Caspase-9 in Cerebral Ischemia

Caspase-9 在脑缺血中的细胞特异性靶点和功能

• 批准号: 8956911
• 负责人: Jennifer Ann Codding-Bui
• 金额: $ 4.07万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-14 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8956911
• 关键词: Address; Alteplase; Angioneurotic Edema; Apoptosis; Aspartic Endopeptidases; Blood - brain barrier anatomy; Blood Vessels; Blood flow; Brain; Caliber; Caspase; Cause of Death; Cell Death; Cells; Central Nervous System Diseases; Cerebral Edema; Cerebral Ischemia; Cerebrum; Cleaved cell; Coagulation Process; Cysteine; Data; Development; Edema; Endothelial Cells; Environment; Exposure to; FDA approved; Faculty; Family; Glucose; Human; Impairment; In Vitro; Infarction; Inflammation; Injury; Intervention; Ischemia; Ischemic Stroke; Knock-out; Knockout Mice; Laboratories; Liquid substance; Location; Measures; Mediator of activation protein; Mentors; Metalloproteases; Molecular; Mus; Neuraxis; Neuronal Injury; Neurons; North America; Oxygen; Pathogenesis; Pathway interactions; Play; Proteins; Pulmonary Edema; Regulation; Reperfusion Therapy; Research; Resistance; Resources; Risk; Role; Signal Pathway; Stroke; Stroke prevention; Testing; Therapeutic; Tight Junctions; Tissue Inhibitor of Metalloproteinases; Tissues; Training Programs; Traumatic Brain Injury; Universities; Vascular blood supply; Work; brain tissue; caspase-9; design; disability; effective therapy; in vivo; in vivo Model; inhibitor/antagonist; macular edema; mortality; neuron loss; neuroprotection; novel; public health relevance; therapy development

DESCRIPTION (provided by applicant): A stroke occurs when the blood supply to a portion of the brain is disrupted, depriving brain tissue of oxygen and glucose, and commonly causing cell death. The sole US FDA-approved treatment for ischemic stroke (87 % of all cases), tissue-type plasminogen activator (tPA), dissolves the clot, allowing for reperfusion of the ischemic tissue. However, reperfusion can exacerbate damage to the blood-brain barrier and prompt an abnormal accumulation of fluid in the brain, called edema. Cerebral edema is caused by a loss of vascular integrity of small blood vessels, and is the primary cause of mortality within the firs three days following a stroke. A better understanding of the molecular mechanisms underlying the development of ischemic-induced edema is required for optimal therapeutic treatment. The Troy laboratory has shown that active caspase-9 plays a critical role in the formation of cerebral edema and in neuronal injury. Reversibly inhibiting caspase-9 with a novel, cell-permeant caspase-9 inhibitor provides neuroprotection out to three weeks and abolishes edema in mice. This work proposes a novel mechanism for the development of ischemic induced edema and will utilize in vitro and in vivo approaches to determine caspase-9's role in edema formation. Aim 1 aspires to elucidate the edema-related substrates of caspase-9 to determine the mechanistic details of this medically significant mechanism. Aim 2 seeks to dissect the cell-specific contributions of caspase-9 activation during stroke in endothelial cells and neurons using cell-specific deletion of caspase-9 in mice to identify the location of this mechanism and the order of progression of stroke pathogenesis. This edema-specific mechanism may be broadly applicable to edema in other central nervous system disorders, such as traumatic brain injury and macular edema, and outside the central nervous system in pulmonary edema and angioedema. The intranasal efficacy of this caspase-9 inhibitor affords the potential for developing this therapy a an intervention in human stroke. Columbia University provides an exceptional scientific environment to carry out this research, with high caliber faculty, colleagues, and resources. The training program will provide exposure to seminars, classes in grantsmanship, mentoring opportunities, and interactions with multiple research groups at Columbia and at other universities.

描述（由申请人提供）：当大脑的一部分的血液供应中断时发生中风，剥夺脑组织的氧气和葡萄糖，通常导致细胞死亡。唯一的美国FDA批准的缺血性卒中治疗（所有病例的87%），组织型纤溶酶原激活剂（tPA），溶解凝块，允许缺血组织再灌注。然而，再灌注可加重对血脑屏障的损伤，并促使脑中液体的异常积聚，称为水肿。脑水肿是由小血管的血管完整性丧失引起的，并且是中风后前三天内死亡的主要原因。更好地了解缺血性水肿发生的分子机制是最佳治疗的必要条件。Troy实验室已经表明，活性caspase-9在脑水肿的形成和神经元损伤中起着关键作用。用一种新型的细胞渗透性caspase-9抑制剂可逆地抑制caspase-9，可在小鼠中提供长达三周的神经保护作用并消除水肿。这项工作提出了一种新的机制，缺血性水肿的发展，并将利用在体外和体内的方法来确定caspase-9的水肿形成的作用。目的1旨在阐明caspase-9的水肿相关底物，以确定这一医学重要机制的机制细节。目的2旨在解剖细胞特异性贡献的caspase-9激活中风期间在内皮细胞和神经元中使用细胞特异性缺失的caspase-9在小鼠中，以确定该机制的位置和中风发病机制的进展顺序。这种水肿特异性机制可能广泛适用于其他中枢神经系统疾病中的水肿，如创伤性脑损伤和黄斑水肿，以及中枢神经系统外的肺水肿和血管性水肿。这种半胱天冬酶-9抑制剂的鼻内功效提供了开发这种疗法作为人类中风干预的潜力。哥伦比亚大学为开展这项研究提供了一个特殊的科学环境，拥有高素质的教师，同事和资源。该培训计划将提供接触研讨会，在格兰芬多类，指导机会，并与多个研究小组在哥伦比亚和其他大学的互动。